Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6000 Shoreline Court, Suite 300 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.veracyte.com |
IR: | See website |
Key People | ||
Marc A. Stapley Chief Executive Officer, Director | Rebecca Chambers Chief Financial Officer | Annie Mcguire Chief People Officer, Executive Vice President | Phillip G. Febbo Chief Scientific Officer, Chief Medical Officer |
Business Overview |
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services. |
Financial Overview |
For the nine months ended 30 September 2023, Veracyte Inc revenues increased 22% to $262.9M. Net loss increased 41% to $46.1M. Revenues reflect Development and commercialization segment increase from $72.9M to $180.4M. Higher net loss reflects Development and commercialization segment loss increase from $10.7M to $39.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.63. |
Employees: | 787 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,625M as of Sep 30, 2023 |
Annual revenue (TTM): | $343.15M as of Sep 30, 2023 |
EBITDA (TTM): | $8.00M as of Sep 30, 2023 |
Net annual income (TTM): | -$49.96M as of Sep 30, 2023 |
Free cash flow (TTM): | $29.08M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 73,039,671 as of Nov 3, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |